跳至主要内容
临床试验/NCT01373736
NCT01373736Unknown3 期

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Vancouver Coastal Health2 个研究点 分布在 1 个国家开始时间: 2011年6月15日最近更新:
适应症
相关药物

试验速览

阶段
3 期
试验地点
2

研究概览

简要总结

The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

研究设计

研究类型
Interventional
主要目的
Diagnostic

入排标准

性别
All
接受健康志愿者

入选标准

  • Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
  • subjects must be able and willing to comply with study procedures.

排除标准

  • Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
  • Subjects unable to tolerate lying supine;
  • Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.

研究者

申办方类型
Other Gov

研究点 (2)

Loading locations...

相似试验